Formulation of extended release orphenadrine citrate tablets to treat muscle spasm and pain

Abstract

Objective: Orphenadrine is an anticholinergic, antimuscarinic, centrally acting skeletal muscle relaxant. It presentsin the form of citrate and HCl salts which are used in treatment of the symptoms of mild Parkinson's disease andalso it is used as adjuvant with other drugs in the therapy. Method: Many trials were made to formulate orphenadrine citrate as tablet using wet granulation or direct compression technique in order to get a satisfactoryformula through studying the effect of various factors such as binders, diluents and disintegrants types. The bestformula was obtained by using poly vinyl pyrrolidone (PVP) as a binder also the results indicated that starch andmannitol gave acceptable physical properties to the tablets when they were used as diluents. At the same time, theresults showed that avicel which was used as a disintegrant gave an acceptable disintegration and dissolution time in comparison with the reference tablet DISIPAL. In addition, the selected formula was used to study the effect ofmethod of incorporation of disintegrant on the physical properties of tablets. Result: It was found that theintragranular incorporation resulted in a shorter disintegration and dissolution times. The stability of orphenadrinecitrate prepared tablets was also studied upon storage at 50C, 60C and 70C for four months. Conclusion: Theoverall results of this study indicate that the drug can be prepared as tablets, which fit the requirements of BritishPharmacopoeia since the prepared tablets gave satisfactory results.